Cencora, Inc. Plans Quarterly Dividend of $0.60 (NYSE:COR)

Key Points

• Cencora declared a quarterly dividend of $0.60 per share payable June 1 to holders of record on May 15, implying a 0.9% yield and $2.40 annualized.
• The company reported Q results with EPS of $4.75 (missing estimates by $0.05) and revenue of $78.36 billion (below expectations), after which the stock fell to $253.20 on heavy trading volume.
• Cencora’s dividend is well-covered (payout ratio ~13.9%) and the company has increased its dividend for 15 consecutive years, while FY2026 guidance targets EPS of $17.65–$17.90 (analyst consensus ~17.58).

Cencora, Inc. (NYSE:COR - Get Free Report) declared a quarterly dividend on Wednesday, May 6th. Investors of record on Friday, May 15th will be paid a dividend of 0.60 per share on Monday, June 1st. This represents a c) annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th.

Cencora has raised its dividend by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 15 years. Cencora has a dividend payout ratio of 13.9% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Cencora to earn $19.59 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 12.3%.

Cencora Price Performance

NYSE:COR traded down $52.71 during trading hours on Wednesday, hitting $253.20. 7,858,017 shares of the stock were exchanged, compared to its average volume of 1,418,244. Cencora has a 52-week low of $244.82 and a 52-week high of $377.54. The firm's fifty day moving average price is $332.27 and its 200 day moving average price is $343.21. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The company has a market cap of $49.25 billion, a P/E ratio of 30.43, a P/E/G ratio of 1.42 and a beta of 0.64.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.80 by ($0.05). Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $78.36 billion for the quarter, compared to analysts' expectations of $81.09 billion. During the same quarter last year, the firm posted $4.42 earnings per share. Cencora's quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts anticipate that Cencora will post 17.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Cencora by 13.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company's stock valued at $15,086,000 after buying an additional 5,543 shares during the last quarter. AustralianSuper Pty Ltd purchased a new position in Cencora in the third quarter valued at $26,191,000. Mediolanum International Funds Ltd increased its holdings in Cencora by 133.0% in the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company's stock valued at $17,342,000 after buying an additional 32,138 shares during the last quarter. Chilton Investment Co. Inc. purchased a new position in Cencora in the third quarter valued at $459,000. Finally, Advisors Asset Management Inc. increased its holdings in Cencora by 40.3% in the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company's stock valued at $5,407,000 after buying an additional 4,973 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.